semaglutide and dementia Semaglutide (Ozempic) did not slow Alzheimer's disease progression in phase 3 EVOKE/EVOKE+ trials of adults 55–85 with MCI or early dementia due to AD

🔬 New study finds Ozempic (semaglutide) users had a 40–50% lower risk of developing Alzheimer's-related dementia compared to those on other diabetes meds over a 3-year period in a 1.7 million patient

25.68

★★★★☆4.8 (126)

New study highlights potential of GLP-1RAs in treating dementia – NIHR Oxford Health Biomedical Research Centre

29.39

★★★★★4.9 (98)

Results from the latest clinical trials show semaglutide, a drug used to treat type 2 diabetes and help with weight loss under the brand names Rybelsus, Ozempic, and Wegovy, does not slow

29.30

★★★★★5.0 (157)

Does Semaglutide (Wegovy) Reduce the Risk of Dementia?

21.51

★★★★★4.7 (84)

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: Earlier this week, we learned that oral Ozempic did not have an impact on Alzheimer's progression. It was a disappointing result, but a study worth trying, and there will be

29.20

★★★★★4.9 (203)

Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study

25.69

★★★★★5.0 (176)

A 2024 Alzheimer's & Dementia study of 1,094,761 type-2 diabetics showed semaglutide cut first-time Alzheimer's diagnoses by ~70% versus conventional antidiabetics. (Wang et al.) We used to talk about GLP-1 agonism as

24.89

★★★★★4.8 (132)